Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional
months to patients who have taken part in the placebo controlled study A0081060; and 2) find
out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.